



Zenlabs Ethica Ltd.

CIN NO. : L74900CH1993PLC033112, GSTIN NO. : 03AAFCS6226G1ZL

Regd. Office : Plot No. 194-195, 3rd Floor, Industrial Area, Phase-II, Chandigarh -160 002

Tel. : 0172-465 1105, Fax : 0172-265 6855

E-mail: queries@zenlabsethica.com, Website : www.zenlabsethica.com

The General Manager
Corporate Relationship Department
BSE LIMITED
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai -400 001

Date: 20th July, 2022

Ref: ZENLABS ETHICA LIMITED (SECURITY CODE NO.: 530697)

Sub.: Approval of Un-audited Financial Results of the company for the quarter ended 30th June, 2022.

Respected Madam/Sir,

Pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, we wish to inform you that the Board of Directors of the Company at their meeting held today on Wednesday the 20th day of July, 2022 at 11:00 a.m. at the registered office of the company at Plot No. 194-195, 3rd Floor, Industrial Area, Phase-II, Chandigarh-160002 have considered and approved the Un-audited Financial Results of the company for the quarter ended on 30th June, 2022. In this regard, we are enclosing herewith:

1. Un-audited Financial Results of the company for the quarter ended on 30th June, 2022;
2. Limited Review Report for the period ended on 30th June, 2022.

You are requested to kindly take the same on record.

Please also note that the company has made necessary arrangement for the publication of Un-audited Financial results as per the requirement of the SEBI (LODR) Regulations, 2015.

Thanking You

Yours Truly,

For Zenlabs Ethica Limited


TANVI CHHABRA
COMPANY SECRETARY





Zenlabs Ethica Ltd.

CIN NO. : L74900CH1993PLC033112, GSTIN NO. : 03AAFCS6226G1ZL

Regd. Office : Plot No. 194-195, 3rd Floor, Industrial Area, Phase-II, Chandigarh -160 002


Tel. : 0172-465 1105, Fax : 0172-265 6855

E-mail: queries@zenlabsethica.com, Website : www.zenlabsethica.com

PART I: STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 30 TH JUNE, 2022					
Sr. No	Particulars	(` In Lakhs except EPS data)			
		Quarter Ended			Year ended
		30-09-2022 (Unaudited)	30-06-2021 (Unaudited)	31-03-2022 (Audited)	31-03-2022 (Audited)
1	Revenue from Operations				
2	Other Income	1,735.39	1,890.36	1,442.56	6,908.76
3	Total Income (1+2)	2.10	2.06	1.13	8.73
4	Expenditure				
	a) Purchase of stock in trade	1,224.66	1,532.12	1,312.93	5,966.41
	b) (Increase)/decrease in stock-in-trade	150.98	22.47	(175.33)	(347.01)
	c) Employees benefit expenses	115.11	65.60	103.21	386.68
	d) Finance costs	11.54	0.81	9.79	37.09
	e) Depreciation and Amortisation	29.50	5.62	23.50	89.11
	f) Other Expenditure	155.04	225.54	159.55	636.08
	Total Expenses	1,686.83	1,852.16	1,433.65	6,791.36
5	Profit before Exceptional & Extraordinary Items (3-4)	50.66	40.28	10.04	126.15
6	Exceptional Items	-	-	-	-
7	Profit Before Tax (5-6)	50.66	40.28	10.04	126.15
8	Tax Expenses				
	a) Current Tax	15.51	10.06	10.81	31.53
	b) MAT Credit entitlement	-	-	-	-
	c) Deferred Tax	(1.41)	-	(3.30)	12.37
9	Profit(+)/ Loss(-) for the period (7-8)	36.56	30.20	2.53	82.25
10	Other Comprehensive Income				
	Items that will not be reclassified to profit or loss				
	Re-measurement of the net defined benefit plans	0.84	0.05	0.24	(1.67)
	Tax on above	(0.23)	-	(0.04)	0.46
11	Total Other comprehensive Income, net of tax	0.61	0.05	0.20	(1.21)
12	Total comprehensive income for the period	37.17	30.25	2.73	81.04
13	Paid up equity share capital				
	(Face Value of ₹ 10/- each per share)	651.00	651.00	651.00	651.00
14	Basic and diluted Earning Per Share (EPS) after Extra Ordinary Items				
	-Basic	0.56	0.46	0.04	1.26
	-Diluted	0.56	0.46	0.04	1.26

NOTES :

- The above financial results for the quarter and year ended 30th June, 2022 have been reviewed by the Audit Committee and were approved and taken on record by the Board of Directors in their respective meeting held on 20th July, 2022. The statutory auditors of the Company have expressed an unmodified opinion in audit report on these on these financial results.
- The Standalone financial results are prepared in accordance with Indian Accounting Standards ("Ind AS"), the provisions of the Companies Act, 2013 ("the Act"), as applicable and guidelines issued by the Securities and Exchange Board of India ("SEBI"). The Ind AS are prescribed under Section 133 of the Act read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.
- The Company is considered to be a single segment company engaged in the trading of pharmaceuticals formulation. Consequently, the Company has, in its primary segment, only one reportable business segment. Accordingly, there are no separate reportable segments as required under Ind AS 108 "Operating Segment".
- The Company has considered the possible impact of pandemic relating to Novel Corona Virus (COVID-19) on its financial results/position using the internal and external sources of information available up to the date of approval of these financial results and expects to recover the carrying value of its assets. In developing the assumptions relating to the possible future uncertainties in the global economic conditions because of the pandemic, the Company has, at the date of approval of these financial results, used internal and external sources of information including credit reports and related information and economic forecasts and expects that the carrying amount of these assets will be recovered. The impact of COVID-19 on the Company's financial results may differ from that anticipated as at the date of approval of these financial results.
- Previous period figures have been re-grouped/ re-classified, wherever necessary, to conform to current period's classifications.


 Director of Board
 for Zenlabs Ethica Limited
 Sanjeev Kumar
 DIN. 01154896
 Managing Director cum Chief Executive Officer

Place: Chandigarh
Date: 20th July, 2022

Independent Auditor's Review Report on Unaudited Quarterly Financial Results of Zenlabs Ethica Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

To

The Board of Directors
Zenlabs Ethica Limited

1. We have reviewed the accompanying statement of unaudited financial results ("the statement") of **Zenlabs Ethica Limited** ("the Company") for the quarter ended 30th June 2022, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including relevant circulars issued by the Securities and Exchange Board of India ("SEBI") from time to time.
2. The statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under Section 133 of Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information performed by Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for the financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters and might be identified in an Audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. The comparative financial information of the Company for the quarter ending ended 30th June 2021 prepared in accordance with Ind AS included in the statement was reviewed/audited by the predecessor auditor vide their unmodified reports dated 22nd July 2021, whose report have been furnished to us by the management and which have been relied upon for the purpose of our review of the statement. Our review report is not modified in respect of this matter.

for N Kumar Chhabra and Co.

Chartered Accountants

ICAI Firm Registration Number 00837N

ASHISH

CHHABRA

Digitally signed by
ASHISH CHHABRA
Date: 2022.07.20
13:32:55 +05'30'

CA. Ashish Chhabra

Partner

Membership Number 507083

Place: Chandigarh

Date: 20th July 2022

UDIN: 22507083ANHDBF5399